Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: A preliminary report

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Nakamura, Ikuko ^a   Oyama, Jun ichi ^a   Komoda, Hiroshi ^a   Shiraki, Aya ^a   Sakamoto, Yoshiko ^a   Taguchi, Isao ^b   Hiwatashi, Atsushi ^a   Komatsu, Aiko ^a   Takeuchi, Masayoshi ^c   Yamagishi, Sho ichi ^d   Inoue, Teruo ^b   Node, Koichi ^a  

^a SAGA UNIVERSITY   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced glycation end products; Cytokines chemokines; Diabetes mellitus type 2; Glimepiride; Growth factors

Indexed keywords

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCEMIC INDEX; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84892428716     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-15     Document Type: Article

References (45)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:4-14. 10.1016/j.diabres.2009.10.007, 19896746.
2. Fujimoto WY, Bergstrom RW, Leonetti DL, Newell-Morris LL, Shuman WP, Wahl PW. Metabolic and adipose risk factors for NIDDM and coronary disease in third-generation Japanese-American men and women with impaired glucose tolerance. Diabetologia 1994, 37:524-532. 10.1007/s001250050142, 8056192.
3. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14:173-194. 10.2337/diacare.14.3.173, 2044434.
4. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002, 105:2696-2698. 10.1161/01.CIR.0000020650.86137.84, 12057978.
5. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607. 10.2337/diab.37.12.1595, 3056758.
6. Couet C, Delarue J, Constans T, et al. Aged-related insulin resistance: a review. Horm Res 1992, 38:46-50. 10.1159/000182483, 1306515.
7. Muller G, Wied S. The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation and dephosphorylation in insulin-resistant rat adipocytes in vitro. Diabetes 1993, 42:1852-1867. 10.2337/diab.42.12.1852, 8243832.
8. Sato J, Ohsawa I, Oshida Y, Sato Y, Sakamoto N. Effects of glimepiride on in vivo insulin action in normal and diabetic rats. Diabet. Res Clin Pract 1993, 22:3-9.
9. Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 2000, 6:114-125. 1949938, 10859028.
10. Yamagishi S, Adachi H, Nakamura K. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006, 55:1227-1231. 10.1016/j.metabol.2006.05.007, 16919543.
11. Nakano Y, Tajima S, Yoshimi A, Akiyama H, Tsushima M, Tanioka T, Negoro T, Tomita M, Tobe T. A novel enzyme-linked immunosorbent assay specific for high-molecular weight adiponectin. J Lipid Res 2006, 47:1572-1582. 10.1194/jlr.D600010-JLR200, 16603722.
12. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, Sagara M, Miyamoto K, Satoh H, Kohno I, Kurata T, Ota H, Mantovani A, Hamakubo T, Daida H, Kodama T. Establishment of high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007, 27:161-167. 10.1161/01.ATV.0000252126.48375.d5, 17095712.
13. Komoda H, Inoue T, Node K. Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker. Clin Exp Hypertens 2010, 32:121-128. 10.3109/10641960903254414, 20374186.
14. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006, 174:169-174. 10.1503/cmaj.050748, 1329454, 16415461.
15. Jojima T, Suzuki K, Hirama N, Uchida K, Hattori Y. Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-kappaB activation through a phosphoinoside 3-kinase-Akt-dependent pathway. Diabetes Obes Metab 2009, 11:143-149.
16. Geisen K, Végh A, Krause E, Papp JG. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res 1996, 28:496-507. 10.1055/s-2007-979841, 8911987.
17. Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998, 32:1044-1052. 10.1345/aph.17360, 9793597.
18. Goldberg RB, Holvey SM, Schneider J. A dose response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 1996, 19:847-856.
19. Végh A, Papp JG. Haemodynamic and other effects of sulphonylurea drugs on the heart. Diabetes Res Clin Pract 1996, 31:S43-S53.
20. Md Isa SH, Najihah I, Nazaimoon WM, Kamarudin NA, Umar NA, Mat NH, Khalid BA. Improvement in C-reactive protein and advanced glycosylation end-products in poorly controlled diabetics is independent of glucose control. Diabetes Res Clin Pract 2006, 72:48-52. 10.1016/j.diabres.2005.09.011, 16253380.
21. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther 2003, 25:472-484. 10.1016/S0149-2918(03)80090-5, 12749508.
22. Koshiba K, Nomura M, Nakaya Y, Ito S. Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. J Med Invest 2006, 53:87-94. 10.2152/jmi.53.87, 16538000.
23. Ridderstråle M, Svaerd R, Zeller C, Kim G, Woerle HJ, Broedl UC, EMPA-REG H2H-SU™ trial investigators Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovasc Diabetol 2013, 12:129. 10.1186/1475-2840-12-129, 3844307, 24007456, EMPA-REG H2H-SU™ trial investigators.
24. Derosa G, Putignano P, Bossi AC, Bonaventura A, Querci F, Franzetti IG, Guazzini B, Testori G, Fogari E, Maffioli P. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol 2011, 666:251-256. 10.1016/j.ejphar.2011.05.051, 21645507.
25. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB, Perez A, Provost JC, Haffner SM. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006, 296:2572-2581. 10.1001/jama.296.21.joc60158, 17101640.
26. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM, PERISCOPE Investigators Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008, 299:1561-1573. 10.1001/jama.299.13.1561, 18378631, PERISCOPE Investigators.
27. Huebschmann AG, Regensteiner JG, Vlassara H, Reusch JE. Diabetes and advanced glycoxidation end products. Diabetes Care 2006, 29:1420-1432. 10.2337/dc05-2096, 16732039.
28. Xu Y, Feng L, Wang S, Zhu Q, Zheng Z, Xiang P, He B, Tang D. Calycosin protects HUVECs from advanced glycation end products-induced macrophage infiltration. J Ethnopharmacol 2011, 137:359-730. 10.1016/j.jep.2011.05.041, 21669275.
29. Ide Y, Matsui T, Ishibashi Y, Takeuchi M, Yamagishi S. Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-κB activation. Microvasc Res 2010, 80:227-232. 10.1016/j.mvr.2010.03.015, 20381502.
30. Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, Takeuchi M, Ohno S, Yoshimura A, Makita Z. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002, 16:1928-1930.
31. Ueda S, Yamagishi S, Matsui T, Noda Y, Ueda S, Jinnouchi Y, Sasaki K, Takeuchi M, Imaizumi T. Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects. Cardiovasc Ther 2012, 30:249-254. 10.1111/j.1755-5922.2011.00264.x, 21884000.
32. Gaudreau S, Guindi C, Ménard M, Benabdallah A, Dupuis G, Amrani A. GM-CSF induces bone marrow precursors of NOD mice to skew into tolerogenic dendritic cells that protect against diabetes. Cell Immunol 2010, 265:31-36. 10.1016/j.cellimm.2010.06.010, 20637454.
33. Gaudreau S, Guindi C, Ménard M, Besin G, Dupuis G, Amrani A. Granulocyte-macrophage colony-stimulating factor prevents diabetes development in NOD mice by inducing tolerogenic dendritic cells that sustain the suppressive function of CD4 + CD25+ regulatory T cells. J Immunol 2007, 179:3638-3647.
34. Fang Y, Shen J, Yao M, Beagley KW, Hambly BD, Bao S, et al. Granulocyte-macrophage colony-stimulating factor enhances wound healing in diabetes via upregulation of proinflammatory cytokines. Br J Dermatol 2010, 162:478-486. 10.1111/j.1365-2133.2009.09528.x, 19799605.
35. Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G. Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 1987, 8:95-114. 10.1210/edrv-8-2-95, 2440668.
36. Sato Y, Hamanaka R, Ono J, Kuwano M, Rifkin DB, Takaki R. The stimulatory effect of PDGF on vascular smooth muscle cell migration is mediated by the induction of endogenous basic FGF. Biochem Biophys Res Commun 1991, 174:1260-1266. 10.1016/0006-291X(91)91557-S, 1996989.
37. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991, 88:3739-3743. 10.1073/pnas.88.9.3739, 51528, 2023924.
38. Esch F, Baird A, Ling N, Ueno N, Hill F, Denoroy L, Klepper R, Gospodarowicz D, Böhlen P, Guillemin R. Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc Nat Acad Sci 1985, 19:6507-6511.
39. Nissen NN, Polverini PJ, Gamelli RL, DiPietro LA. Basic fibroblast growth factor mediates angiogenic activity in early surgical wounds. Surgery 1996, 119:457-465. 10.1016/S0039-6060(96)80148-6, 8644013.
40. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase ofwound healing. Am J Pathol 1998, 152:1445-1542. 1858442, 9626049.
41. Tilton RG, Kawamura T, Chang KC, Ido Y, Bjercke RJ, Stephan CC, Brock TA, Williamson JR. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest 1997, 99:2192-2202. 10.1172/JCI119392, 508049, 9151791.
42. Chatzigeorgiou A, Harokopos V, Mylona-Karagianni C, Tsouvalas E, Aidinis V, Kamper EF. The pattern of inflammatory/anti-inflammatory cytokines and chemokines in type 1 diabetic patients over time. Ann Med 2010, 42:426-438. 10.3109/07853890.2010.495951, 20568978.
43. Hessner MJ, Wang X, Meyer L, Geoffrey R, Jia S, Fuller J, Lernmark A, Ghosh S. Involvement of eotaxin, eosinophils, and pancreatic predisposition in development of type 1 diabetes mellitus in the BioBreeding rat. J Immunol 2004, 173:6993-7002.
44. Ghanim H, Korzeniewski K, Sia CL, Abuaysheh S, Lohano T, Chaudhuri A, Dandona P. Suppressive effect of insulin infusion on chemokines and chemokine receptors. Diabetes Care 2010, 33:1103-1108. 10.2337/dc09-2193, 2858184, 20200310.
45. Fukui M, Tanaka M, Hamaguchi M, Senmaru T, Sakabe K, Shiraishi E, Harusato I, Yamazaki M, Hasegawa G, Nakamura N. Eosinophil count is positively correlated with albumin excretion rate in men with type 2 diabetes. Clin J Am Soc Nephrol 2009, 4:1761-1765. 10.2215/CJN.03330509, 2774959, 19808222.